Evidence map›Paper›PMID 35549815›Full record

ArticleBioengineered2022

Bone mesenchymal stem cells (BMSCs)-derived exosomal microRNA-21-5p regulates Kruppel-like factor 3 (KLF3) to promote osteoblast proliferation

Murong You, Zisheng Ai, Jihuan Zeng, Yang Fu, Liang Zhang, Xin Wu

Open access · goldAbstract read
In one paragraph

Article in Bioengineered, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Roles of skeletal muscle-derived exosomes in osteoporosis.Journal of translational medicine · 2025
    Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. KLF transcription factors in bone diseases.Journal of cellular and molecular medicine · 2024
    Review
  14. Review
  15. Article
  16. The Potential of Exosomes for Osteoporosis Treatment: A Review.Drug design, development and therapy · 2024
    Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Murong YouDepartment of Orthopedics, JiangXi Provincial People's Hospital, Nanchang, Jiangxi Province, People's Republic of China.
Zisheng AiDepartment of Medical Statistics, Tongji University School of Medicine, Shanghai, People's Republic of China.
Jihuan ZengDepartment of Orthopedics, JiangXi Provincial People's Hospital, Nanchang, Jiangxi Province, People's Republic of China.
Yang FuDepartment of Orthopedics, JiangXi Provincial People's Hospital, Nanchang, Jiangxi Province, People's Republic of China.
Liang ZhangDepartment of Orthopedics, JiangXi Provincial People's Hospital, Nanchang, Jiangxi Province, People's Republic of China.
Xin WuDepartment of Orthopedics, JiangXi Provincial People's Hospital, Nanchang, Jiangxi Province, People's Republic of China.
Jiangxi Provincial People's Hospital · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone mesenchymal stem cells (BMSCs)-derived exosomes (Exos) play important roles in osteoporosis, while the regulation of microRNA (miR)-21-5p remains unclear. The BMSCs-derived exosomes were isolated from femoral bone marrow of trauma patients, which were then used to stimulate human osteoblasts (hFOB1.19 cells). The miR-21-5p mimic or inhibitor was transfected into BMSCs to overexpress or knockdown miR-21-5p. The functions of miR-21-5p in osteoporosis were assessed by cell counting kit-8 (CCK-8) assay, alkaline phosphatase (ALP) staining and alizarin red staining assays. We found that BMSCs-derived exosomes could enhance proliferation, osteoblastic differentiation and ALP activity of hFOB1.19 cells. BMSCs-derived exosomes with upregulated miR-21-5p could further enhance these protective impacts compared with that in BMSCs-derived exosomes, while BMSCs-derived exosomes with downregulated miR-21-5p reduced these cell phenotypes. MiR-21-5p could directly bind to the 3'-untranslated region (UTR) of Kruppel-like factor 3 (KLF3), and knockdown of KLF3 obviously attenuated these inhibitory effects of BMSCs-derived exosomes with downregulated miR-21-5p on osteoblastic differentiation and ALP activity of hFOB1.19 cells. In summary, BMSCs-derived exosomal miR-21-5p improved osteoporosis through regulating KLF3, providing a potential therapeutic strategy for osteoporosis.

Indexed as

Mesenchymal Stem CellsMicroRNAsOsteoporosisCell ProliferationHumansKruppel-Like Transcription FactorsOsteoblastsTranscription FactorsKLF3 protein, humanKruppel-Like Transcription FactorsMicroRNAsMIRN21 microRNA, humanTranscription FactorsBone mesenchymal stem cells (BMSCs)exosomesKruppel-like factor 3 (KLF3)miR-21-5posteoporosis

Identifiers

PMID35549815
PMCPMC9310648
OpenAlexW4280546844

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.